Compile Data Set for Download or QSAR

Found 100 hits Enz. Inhib. hit(s) with all data for assayid = 1 entry = 2248   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359101 (US10220048, Compound AA11 | US10952992, No. AA11 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)C1CC1 |r| Show InChI InChI=1S/C25H28N4O6S2/c1-35-25(31)28-20(13-16-5-3-2-4-6-16)23(30)26-21(24-27-22(15-36-24)18-9-10-18)14-17-7-11-19(12-8-17)29-37(32,33)34/h2-8,11-12,15,18,20-21,29H,9-10,13-14H2,1H3,(H,26,30)(H,28,31)(H,32,33,34)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359121 (US10220048, Compound AA31 | US10952992, No. AA31 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(CS(=O)(=O)c2ccc(Cl)cc2)n1 |r| Show InChI InChI=1S/C29H29ClN4O8S3/c1-42-29(36)33-25(16-19-5-3-2-4-6-19)28(35)32-24(15-20-7-11-22(12-8-20)34-45(39,40)41)26-17-43-27(31-26)18-44(37,38)23-13-9-21(30)10-14-23/h2-14,17,24-25,34H,15-16,18H2,1H3,(H,32,35)(H,33,36)(H,39,40,41)/t24-,25-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.0800	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359106 (US10220048, Compound AA16 | US10952992, No. AA16 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(CCC(F)(F)F)cs1 |r| Show InChI InChI=1S/C25H27F3N4O6S2/c1-38-24(34)31-20(13-16-5-3-2-4-6-16)22(33)30-21(23-29-19(15-39-23)11-12-25(26,27)28)14-17-7-9-18(10-8-17)32-40(35,36)37/h2-10,15,20-21,32H,11-14H2,1H3,(H,30,33)(H,31,34)(H,35,36,37)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.0800	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359113 (US10220048, Compound AA23 | US10952992, No. AA23 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)-c1ccsc1 |r| Show InChI InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(13-17-5-3-2-4-6-17)24(31)27-22(25-28-23(16-38-25)19-11-12-37-15-19)14-18-7-9-20(10-8-18)30-39(33,34)35/h2-12,15-16,21-22,30H,13-14H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.0900	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359099 (US10220048, Compound AA9 | US10952992, No. AA9 | U...) Show SMILES CCCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C25H30N4O6S2/c1-3-7-20-16-36-24(26-20)22(15-18-10-12-19(13-11-18)29-37(32,33)34)27-23(30)21(28-25(31)35-2)14-17-8-5-4-6-9-17/h4-6,8-13,16,21-22,29H,3,7,14-15H2,1-2H3,(H,27,30)(H,28,31)(H,32,33,34)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.100	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359118 (US10220048, Compound AA28 | US10952992, No. AA28 |...) Show SMILES CCc1nc(cs1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C24H28N4O6S2/c1-3-22-25-21(15-35-22)19(13-17-9-11-18(12-10-17)28-36(31,32)33)26-23(29)20(27-24(30)34-2)14-16-7-5-4-6-8-16/h4-12,15,19-20,28H,3,13-14H2,1-2H3,(H,26,29)(H,27,30)(H,31,32,33)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.100	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359104 (US10220048, Compound AA14 | US10952992, No. AA14 |...) Show SMILES CCc1nc(sc1C)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C25H30N4O6S2/c1-4-20-16(2)36-24(27-20)22(15-18-10-12-19(13-11-18)29-37(32,33)34)26-23(30)21(28-25(31)35-3)14-17-8-6-5-7-9-17/h5-13,21-22,29H,4,14-15H2,1-3H3,(H,26,30)(H,28,31)(H,32,33,34)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.100	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359117 (US10220048, Compound AA27 | US10952992, No. AA27 |...) Show SMILES CCOC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(CC)cs1 |r| Show InChI InChI=1S/C25H30N4O6S2/c1-3-19-16-36-24(26-19)22(15-18-10-12-20(13-11-18)29-37(32,33)34)27-23(30)21(28-25(31)35-4-2)14-17-8-6-5-7-9-17/h5-13,16,21-22,29H,3-4,14-15H2,1-2H3,(H,27,30)(H,28,31)(H,32,33,34)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.140	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359091 (US10220048, Compound AA1 | US10220048, Compound AA...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)Cc1ccccc1 |r| Show InChI InChI=1S/C21H23N3O4S2/c1-2-17-14-29-21(22-17)19(23-20(25)13-15-6-4-3-5-7-15)12-16-8-10-18(11-9-16)24-30(26,27)28/h3-11,14,19,24H,2,12-13H2,1H3,(H,23,25)(H,26,27,28)/t19-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.157	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359096 (US10220048, Compound AA6 | US10952992, No. AA6 | U...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C24H28N4O6S2/c1-3-18-15-35-23(25-18)21(14-17-9-11-19(12-10-17)28-36(31,32)33)26-22(29)20(27-24(30)34-2)13-16-7-5-4-6-8-16/h4-12,15,20-21,28H,3,13-14H2,1-2H3,(H,26,29)(H,27,30)(H,31,32,33)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.162	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359187 (US10220048, Compound AA97 | US10952992, No. AA97 |...) Show SMILES CCCc1nnc(N[C@@H](Cc2ccc(NS(O)(=O)=O)cc2)c2csc(n2)-c2cccs2)s1 |r| Show InChI InChI=1S/C20H21N5O3S4/c1-2-4-18-23-24-20(31-18)22-15(16-12-30-19(21-16)17-5-3-10-29-17)11-13-6-8-14(9-7-13)25-32(26,27)28/h3,5-10,12,15,25H,2,4,11H2,1H3,(H,22,24)(H,26,27,28)/t15-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359108 (US10220048, Compound AA18 | US10952992, No. AA18 |...) Show SMILES CCOC(=O)c1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C25H28N4O8S2/c1-3-37-24(31)21-15-38-23(27-21)20(14-17-9-11-18(12-10-17)29-39(33,34)35)26-22(30)19(28-25(32)36-2)13-16-7-5-4-6-8-16/h4-12,15,19-20,29H,3,13-14H2,1-2H3,(H,26,30)(H,28,32)(H,33,34,35)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359100 (US10220048, Compound AA10 | US10952992, No. AA10 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)C(C)(C)C |r| Show InChI InChI=1S/C26H32N4O6S2/c1-26(2,3)22-16-37-24(29-22)21(15-18-10-12-19(13-11-18)30-38(33,34)35)27-23(31)20(28-25(32)36-4)14-17-8-6-5-7-9-17/h5-13,16,20-21,30H,14-15H2,1-4H3,(H,27,31)(H,28,32)(H,33,34,35)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359120 (US10220048, Compound AA30 | US10952992, No. AA30 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)C1CC1 |r| Show InChI InChI=1S/C25H28N4O6S2/c1-35-25(31)28-21(14-16-5-3-2-4-6-16)23(30)26-20(22-15-36-24(27-22)18-9-10-18)13-17-7-11-19(12-8-17)29-37(32,33)34/h2-8,11-12,15,18,20-21,29H,9-10,13-14H2,1H3,(H,26,30)(H,28,31)(H,32,33,34)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359178 (US10220048, Compound AA88 | US10952992, No. AA88 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)CCc1cccc(Cl)c1 |r| Show InChI InChI=1S/C22H24ClN3O4S2/c1-2-18-14-31-22(24-18)20(13-16-6-9-19(10-7-16)26-32(28,29)30)25-21(27)11-8-15-4-3-5-17(23)12-15/h3-7,9-10,12,14,20,26H,2,8,11,13H2,1H3,(H,25,27)(H,28,29,30)/t20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359131 (US10220048, Compound AA41 | US10952992, No. AA41 |...) Show SMILES CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)-c1ccsc1 |r| Show InChI InChI=1S/C26H26N4O5S3/c1-17(31)27-22(13-18-5-3-2-4-6-18)25(32)28-23(26-29-24(16-37-26)20-11-12-36-15-20)14-19-7-9-21(10-8-19)30-38(33,34)35/h2-12,15-16,22-23,30H,13-14H2,1H3,(H,27,31)(H,28,32)(H,33,34,35)/t22-,23-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.240	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359109 (US10220048, Compound AA19 | US10952992, No. AA19 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1ncc(s1)-c1ccccc1 |r| Show InChI InChI=1S/C28H28N4O6S2/c1-38-28(34)31-23(16-19-8-4-2-5-9-19)26(33)30-24(17-20-12-14-22(15-13-20)32-40(35,36)37)27-29-18-25(39-27)21-10-6-3-7-11-21/h2-15,18,23-24,32H,16-17H2,1H3,(H,30,33)(H,31,34)(H,35,36,37)/t23-,24-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359105 (US10220048, Compound AA15 | US10952992, No. AA15 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(CC(F)(F)F)cs1 |r| Show InChI InChI=1S/C24H25F3N4O6S2/c1-37-23(33)30-19(11-15-5-3-2-4-6-15)21(32)29-20(22-28-18(14-38-22)13-24(25,26)27)12-16-7-9-17(10-8-16)31-39(34,35)36/h2-10,14,19-20,31H,11-13H2,1H3,(H,29,32)(H,30,33)(H,34,35,36)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359130 (US10220048, Compound AA40 | US10952992, No. AA40 |...) Show SMILES CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)C(C)(C)C |r| Show InChI InChI=1S/C26H32N4O5S2/c1-17(31)27-21(14-18-8-6-5-7-9-18)24(32)28-22(25-29-23(16-36-25)26(2,3)4)15-19-10-12-20(13-11-19)30-37(33,34)35/h5-13,16,21-22,30H,14-15H2,1-4H3,(H,27,31)(H,28,32)(H,33,34,35)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359167 (US10220048, Compound AA77 | US10952992, No. AA77 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)Cc1cccc(F)c1 |r| Show InChI InChI=1S/C21H22FN3O4S2/c1-2-17-13-30-21(23-17)19(24-20(26)12-15-4-3-5-16(22)10-15)11-14-6-8-18(9-7-14)25-31(27,28)29/h3-10,13,19,25H,2,11-12H2,1H3,(H,24,26)(H,27,28,29)/t19-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359138 (US10220048, Compound AA48 | US10952992, No. AA48 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(=O)OC |r| Show InChI InChI=1S/C26H30N4O7S2/c1-3-19-16-38-26(27-19)22(14-18-9-11-20(12-10-18)30-39(34,35)36)29-25(33)21(13-17-7-5-4-6-8-17)28-23(31)15-24(32)37-2/h4-12,16,21-22,30H,3,13-15H2,1-2H3,(H,28,31)(H,29,33)(H,34,35,36)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359137 (US10220048, Compound AA47 | US10952992, No. AA47 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)OC |r| Show InChI InChI=1S/C21H30N4O6S2/c1-5-15-12-32-20(22-15)18(11-14-6-8-16(9-7-14)25-33(28,29)30)23-19(26)17(10-13(2)3)24-21(27)31-4/h6-9,12-13,17-18,25H,5,10-11H2,1-4H3,(H,23,26)(H,24,27)(H,28,29,30)/t17-,18-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359115 (US10220048, Compound AA25 | US10952992, No. AA25 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc2CCCCc2s1 |r| Show InChI InChI=1S/C26H30N4O6S2/c1-36-26(32)29-21(15-17-7-3-2-4-8-17)24(31)27-22(25-28-20-9-5-6-10-23(20)37-25)16-18-11-13-19(14-12-18)30-38(33,34)35/h2-4,7-8,11-14,21-22,30H,5-6,9-10,15-16H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359127 (US10220048, Compound AA37 | US10952992, No. AA37 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1ccco1 |r| Show InChI InChI=1S/C26H26N4O7S2/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359188 (US10220048, Compound AA98 | US10952992, No. AA98 |...) Show SMILES OS(=O)(=O)Nc1ccc(C[C@H](Nc2nnc(Cc3ccccc3)s2)c2csc(n2)-c2cccs2)cc1 |r| Show InChI InChI=1S/C24H21N5O3S4/c30-36(31,32)29-18-10-8-17(9-11-18)13-19(20-15-34-23(25-20)21-7-4-12-33-21)26-24-28-27-22(35-24)14-16-5-2-1-3-6-16/h1-12,15,19,29H,13-14H2,(H,26,28)(H,30,31,32)/t19-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359132 (US10220048, Compound AA42 | US10220048, Compound A...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C |r| Show InChI InChI=1S/C24H36N4O6S2/c1-7-17-14-35-22(25-17)20(13-16-8-10-18(11-9-16)28-36(31,32)33)26-21(29)19(12-15(2)3)27-23(30)34-24(4,5)6/h8-11,14-15,19-20,28H,7,12-13H2,1-6H3,(H,26,29)(H,27,30)(H,31,32,33)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359129 (US10220048, Compound AA39 | US10952992, No. AA39 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(C)=O |r| Show InChI InChI=1S/C24H28N4O5S2/c1-3-19-15-34-24(26-19)22(14-18-9-11-20(12-10-18)28-35(31,32)33)27-23(30)21(25-16(2)29)13-17-7-5-4-6-8-17/h4-12,15,21-22,28H,3,13-14H2,1-2H3,(H,25,29)(H,27,30)(H,31,32,33)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359119 (US10220048, Compound AA29 | US10952992, No. AA29 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(C)n1 |r| Show InChI InChI=1S/C23H26N4O6S2/c1-15-24-21(14-34-15)19(12-17-8-10-18(11-9-17)27-35(30,31)32)25-22(28)20(26-23(29)33-2)13-16-6-4-3-5-7-16/h3-11,14,19-20,27H,12-13H2,1-2H3,(H,25,28)(H,26,29)(H,30,31,32)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359114 (US10220048, Compound AA24 | US10952992, No. AA24 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc2CCCc2s1 |r| Show InChI InChI=1S/C25H28N4O6S2/c1-35-25(31)28-20(14-16-6-3-2-4-7-16)23(30)26-21(24-27-19-8-5-9-22(19)36-24)15-17-10-12-18(13-11-17)29-37(32,33)34/h2-4,6-7,10-13,20-21,29H,5,8-9,14-15H2,1H3,(H,26,30)(H,28,31)(H,32,33,34)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359107 (US10220048, Compound AA17 | US10952992, No. AA17 |...) Show SMILES COCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C24H28N4O7S2/c1-34-14-19-15-36-23(25-19)21(13-17-8-10-18(11-9-17)28-37(31,32)33)26-22(29)20(27-24(30)35-2)12-16-6-4-3-5-7-16/h3-11,15,20-21,28H,12-14H2,1-2H3,(H,26,29)(H,27,30)(H,31,32,33)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359098 (US10220048, Compound AA8 | US10952992, No. AA8 | U...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(C)cs1 |r| Show InChI InChI=1S/C23H26N4O6S2/c1-15-14-34-22(24-15)20(13-17-8-10-18(11-9-17)27-35(30,31)32)25-21(28)19(26-23(29)33-2)12-16-6-4-3-5-7-16/h3-11,14,19-20,27H,12-13H2,1-2H3,(H,25,28)(H,26,29)(H,30,31,32)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359103 (US10220048, Compound AA13 | US10952992, No. AA13 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(C)c(C)s1 |r| Show InChI InChI=1S/C24H28N4O6S2/c1-15-16(2)35-23(25-15)21(14-18-9-11-19(12-10-18)28-36(31,32)33)26-22(29)20(27-24(30)34-3)13-17-7-5-4-6-8-17/h4-12,20-21,28H,13-14H2,1-3H3,(H,26,29)(H,27,30)(H,31,32,33)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359189 (US10220048, Compound AA99 | US10952992, No. AA99 |...) Show SMILES COC(=O)Cc1nnc(N[C@@H](Cc2ccc(NS(O)(=O)=O)cc2)c2csc(n2)-c2cccs2)s1 |r| Show InChI InChI=1S/C20H19N5O5S4/c1-30-18(26)10-17-23-24-20(33-17)22-14(15-11-32-19(21-15)16-3-2-8-31-16)9-12-4-6-13(7-5-12)25-34(27,28)29/h2-8,11,14,25H,9-10H2,1H3,(H,22,24)(H,27,28,29)/t14-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359175 (US10220048, Compound AA85 | US10952992, No. AA85 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)CCc1ccccc1 |r| Show InChI InChI=1S/C22H25N3O4S2/c1-2-18-15-30-22(23-18)20(24-21(26)13-10-16-6-4-3-5-7-16)14-17-8-11-19(12-9-17)25-31(27,28)29/h3-9,11-12,15,20,25H,2,10,13-14H2,1H3,(H,24,26)(H,27,28,29)/t20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359182 (US10220048, Compound AA92 | US10952992, No. AA92 |...) Show SMILES CCN1CCN(CC(=O)N[C@@H](Cc2ccc(NS(O)(=O)=O)cc2)c2nc(CC)cs2)C(=O)C1=O |r| Show InChI InChI=1S/C21H27N5O6S2/c1-3-15-13-33-19(22-15)17(11-14-5-7-16(8-6-14)24-34(30,31)32)23-18(27)12-26-10-9-25(4-2)20(28)21(26)29/h5-8,13,17,24H,3-4,9-12H2,1-2H3,(H,23,27)(H,30,31,32)/t17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359183 (US10220048, Compound AA93 | US10952992, No. AA93 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)Cn1cc(C)c(=O)[nH]c1=O |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359122 (US10220048, Compound AA32 | US10952992, No. AA32 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(CS(=O)(=O)C(C)(C)C)n1 |r| Show InChI InChI=1S/C27H34N4O8S3/c1-27(2,3)41(34,35)17-24-28-23(16-40-24)21(14-19-10-12-20(13-11-19)31-42(36,37)38)29-25(32)22(30-26(33)39-4)15-18-8-6-5-7-9-18/h5-13,16,21-22,31H,14-15,17H2,1-4H3,(H,29,32)(H,30,33)(H,36,37,38)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359135 (US10220048, Compound AA45 | US10952992, No. AA45 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)C |r| Show InChI InChI=1S/C20H28N4O6S2/c1-5-14-11-31-19(21-14)16(22-18(25)17(12(2)3)23-20(26)30-4)10-13-6-8-15(9-7-13)24-32(27,28)29/h6-9,11-12,16-17,24H,5,10H2,1-4H3,(H,22,25)(H,23,26)(H,27,28,29)/t16-,17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359185 (US10220048, Compound AA95 | US10952992, No. AA95 |...) Show SMILES Cc1nnc(N[C@@H](Cc2ccc(NS(O)(=O)=O)cc2)c2csc(n2)-c2ccccc2)s1 |r| Show InChI InChI=1S/C20H19N5O3S3/c1-13-23-24-20(30-13)22-17(11-14-7-9-16(10-8-14)25-31(26,27)28)18-12-29-19(21-18)15-5-3-2-4-6-15/h2-10,12,17,25H,11H2,1H3,(H,22,24)(H,26,27,28)/t17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359128 (US10220048, Compound AA38 | US10952992, No. AA38 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1cnccn1 |r| Show InChI InChI=1S/C26H26N6O6S2/c1-38-26(34)31-21(14-17-5-3-2-4-6-17)24(33)29-20(13-18-7-9-19(10-8-18)32-40(35,36)37)23-16-39-25(30-23)22-15-27-11-12-28-22/h2-12,15-16,20-21,32H,13-14H2,1H3,(H,29,33)(H,31,34)(H,35,36,37)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359179 (US10220048, Compound AA89 | US10952992, No. AA89 |...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)CCc1ccccc1OC |r| Show InChI InChI=1S/C23H27N3O5S2/c1-3-18-15-32-23(24-18)20(14-16-8-11-19(12-9-16)26-33(28,29)30)25-22(27)13-10-17-6-4-5-7-21(17)31-2/h4-9,11-12,15,20,26H,3,10,13-14H2,1-2H3,(H,25,27)(H,28,29,30)/t20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359092 (US10220048, Compound AA2 | US10952992, No. AA2 | U...) Show SMILES CCc1csc(n1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)OC(C)(C)C |r| Show InChI InChI=1S/C27H34N4O6S2/c1-5-20-17-38-25(28-20)23(16-19-11-13-21(14-12-19)31-39(34,35)36)29-24(32)22(15-18-9-7-6-8-10-18)30-26(33)37-27(2,3)4/h6-14,17,22-23,31H,5,15-16H2,1-4H3,(H,29,32)(H,30,33)(H,34,35,36)/t22-,23+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359126 (US10220048, Compound AA36 | US10952992, No. AA36 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1sccc1C |r| Show InChI InChI=1S/C27H28N4O6S3/c1-17-12-13-38-24(17)26-29-23(16-39-26)21(14-19-8-10-20(11-9-19)31-40(34,35)36)28-25(32)22(30-27(33)37-2)15-18-6-4-3-5-7-18/h3-13,16,21-22,31H,14-15H2,1-2H3,(H,28,32)(H,30,33)(H,34,35,36)/t21-,22-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359125 (US10220048, Compound AA35 | US10952992, No. AA35 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1sccc1Cl |r| Show InChI InChI=1S/C26H25ClN4O6S3/c1-37-26(33)30-21(14-16-5-3-2-4-6-16)24(32)28-20(13-17-7-9-18(10-8-17)31-40(34,35)36)22-15-39-25(29-22)23-19(27)11-12-38-23/h2-12,15,20-21,31H,13-14H2,1H3,(H,28,32)(H,30,33)(H,34,35,36)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359124 (US10220048, Compound AA34 | US10952992, No. AA34 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1csc(n1)-c1cccs1 |r| Show InChI InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	Purchase MCE KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359102 (US10220048, Compound AA12 | US10952992, No. AA12 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)C1CCCCC1 |r| Show InChI InChI=1S/C28H34N4O6S2/c1-38-28(34)31-23(16-19-8-4-2-5-9-19)26(33)29-24(17-20-12-14-22(15-13-20)32-40(35,36)37)27-30-25(18-39-27)21-10-6-3-7-11-21/h2,4-5,8-9,12-15,18,21,23-24,32H,3,6-7,10-11,16-17H2,1H3,(H,29,33)(H,31,34)(H,35,36,37)/t23-,24-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359116 (US10220048, Compound AA26 | US10952992, No. AA26 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)-c1ccc(Cl)s1 |r| Show InChI InChI=1S/C26H25ClN4O6S3/c1-37-26(33)30-19(13-16-5-3-2-4-6-16)24(32)28-20(14-17-7-9-18(10-8-17)31-40(34,35)36)25-29-21(15-38-25)22-11-12-23(27)39-22/h2-12,15,19-20,31H,13-14H2,1H3,(H,28,32)(H,30,33)(H,34,35,36)/t19-,20-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359094 (US10220048, Compound AA4 | US10952992, No. AA4 | U...) Show SMILES CC(C)(C)OC(=O)NC[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)-c1ccccc1 |r| Show InChI InChI=1S/C32H36N4O6S2/c1-32(2,3)42-31(38)33-20-25(18-22-10-6-4-7-11-22)29(37)34-27(19-23-14-16-26(17-15-23)36-44(39,40)41)30-35-28(21-43-30)24-12-8-5-9-13-24/h4-17,21,25,27,36H,18-20H2,1-3H3,(H,33,38)(H,34,37)(H,39,40,41)/t25-,27-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359110 (US10220048, Compound AA20 | US10952992, No. AA20 |...) Show SMILES CCc1nc(sc1-c1ccccc1)[C@H](Cc1ccc(NS(O)(=O)=O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC |r| Show InChI InChI=1S/C30H32N4O6S2/c1-3-24-27(22-12-8-5-9-13-22)41-29(32-24)26(19-21-14-16-23(17-15-21)34-42(37,38)39)31-28(35)25(33-30(36)40-2)18-20-10-6-4-7-11-20/h4-17,25-26,34H,3,18-19H2,1-2H3,(H,31,35)(H,33,36)(H,37,38,39)/t25-,26-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein phosphatase beta (Homo sapiens (Human))	BDBM359112 (US10220048, Compound AA22 | US10952992, No. AA22 |...) Show SMILES COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)-c1cccs1 |r| Show InChI InChI=1S/C26H26N4O6S3/c1-36-26(32)29-20(14-17-6-3-2-4-7-17)24(31)27-21(25-28-22(16-38-25)23-8-5-13-37-23)15-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	<5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...				US Patent US10220048 (2019) BindingDB Entry DOI: 10.7270/Q2VT1VC9
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 100 total )  |  Next  |  Last  >>

Jump to: